Program - KSMO Conference

Scientific Program

Under Construction: Details will be updated shortly.

Sep. 3(Wed)

KSMO Initiatives for Cancer Care Inequity

Cancer Care Inequity with a focus on navigating access challenges pertaining to NGS, Precision Medicine, and therapeutics in the Asia Pacific region

Date & Time	Sep. 3(Wed), 14:00-16:00	Venue	Room D (Walker Hall 2)
Chair(s)	Changhoon Yoo (Asan Medical Center, Korea) Omali Pitiyarachchi (University of New South Wales, Australia)
Session Details	1. Insights from the 2024 KSMO Young Oncologist Forum Omali Pitiyarachchi (University of New South Wales, Australia) 2. Advancing precision oncology in Japan: Evolving clinical trials and real-world practice Tatsunori Shimoi (Medical Oncology, National Cancer Center Hospital Tsukiji, Japan) 3. Current status of NGS reimbursement in Korea Hyehyun Jeong (Asan Medical Center, Korea) 4. Challenges and progress in cancer drug access in the Philippines Mary Antonette G. Ong-Chua (Antique Medical Center, Philippines) 5. The role of patient education in driving uptake of NGS testing from a Thailand Perspective Lucksamon Thamlikitkul (Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand) 6. Panel Discussion Joshua Tan (national cancer centre singapore, Singapore) Jordan Cohen (Calvary Mater Newcastle, Australia) Jiun-I Lai (Medical Oncology, Taipei Veterans General Hospital, Taiwan) Kyaw Zin Win (Mandalar Hospital, Mandalay, Myanmar) Zhuoran Yao (Cancer Center, West China Hospital, Sichuan University, China) Le Minh Hang (Can Tho Oncology Hospital, Vietnam) Javeria Haider (Atomic Energy Cancer Hospital NORI, Islamabad, Pakistan) Izzati Wan Maharuddin (Sarawak General Hospital, Kuching, Malaysia, Malaysia) Erty Sundarita (Sriwijaya University, Indonesia) Amit Kumar (Jay Prabha Medanta Superspeciality Hospital, India)

Education Session 1 (ES01)

Symptom management in advanced cancer: Innovations and best practices

Date & Time	Sep. 3 (Wed), 16:10-17:30	Venue	Room D (Walker Hall 2)
Chair(s)	Seong Hoon Shin (Kosin University Gospel Hospital, Korea) Junghun Kang (Gyeongsang National University Hospital, Korea)
Session Details	1. New approach to manage toxicities of novel anticancer drugs Hee Jun Kim (Chung-Ang University College of Medicine, Korea) 2. Pharmacological innovations in symptom control Seyoung Seo (Asan Medical Center, Korea) 3. Advanced nursing approaches: Outpatient nurse-led telephone counseling for cancer symptom management Ji Youn Kim (Medical Oncology Clinical Nurse Specialist, Asan Medical Center, Korea) 4. Integrating clinical research and coordinated care for optimal symptom management Hee Kyung Ahn (Samsung Medical Center, Korea)

Sep. 4 (Thu)

ASCO/KSMO Joint Symposium 1 (JS01)

New horizon on gastroesophageal cancer treatment

Date & Time	Sep. 4 (Thu), 08:40-10:10	Venue	Room A (Vista Hall 1)
Chair(s)	Tae Won Kim (KSMO Advisory Committee, Asan Medical Center, Korea) Elizabeth Mittendorf (ASCO President-Elect, Dana-Farber Cancer Institute, USA)
Session Details	1.Towards a deeper understanding of current therapies in gastric cancer – Lessons from translational research Samuel Klempner (Massachusetts General Hospital, USA) 2. Lessons learned from platform trials in GC: Optimizing the treatment strategy in GC Jeeyun Lee (Samsung Medical Center, Korea) 3.Landmark trials in HER2-negative gastroesophageal cancer: Where we are and where we are going Samuel Cytryn (Memorial Sloan Kettering Cancer Center, USA) 4.Her2+ gastric cancer: Time to move forward Keun-Wook Lee (Seoul National University Bundang Hospital, Korea)

KCSG/KSMO Joint Symposium 2 (JS02)

Transforming oncology research: AI-powered clinical trials

Date & Time	Sep. 4 (Thu), 08:40-10:10	Venue	Room B (Vista Hall 3)
Chair(s)	Jin Seok Ahn (Samsung Medical Center, Korea) Sook-ryun Park (Asan Medical Center, Korea)
Session Details	1.Clinical research and generative AI Hiromizu Takahashi (Juntendo University Urayasu Hospital, Japan) 2. AI-Driven patient recruitment and trial optimization Kenneth Kehl (Dana-Farber Cancer Institute, USA) 3.Clinical trial design and simulation with AI Sandip Pravin Patel (UC San Diego Moores Cancer Center, USA) 4.Regulatory and ethical considerations in AI-powered clinical trials Hannah Kim (Yonsei University College of Medicine, Korea)

Education Session 2 (ES02)

Tumor heterogeneity and single-cell analysis KOREAN

Date & Time	Sep. 4 (Thu), 08:40-10:10	Venue	Room C (Walker Hall 1)
Chair(s)	Sang Joon Shin (Yonsei University College of Medicine, Korea) Kyoung Mee Kim (Samsung Medical Center, Korea)
Session Details	1. Tumor deconvolution-guided precision medicine in cancer Jinhyuk Bhin (Yonsei University College of Medicine, Korea) 2. Tracing cellular dynamics during intestinal tumorigenesis and metastasis Min Kyu Yum (KAIST, Korea) 3. Mapping and targeting tumor microenvironment in gastric cancer Hoon Hur (Ajou University School of Medicine, Korea) 4. Deciphering head and neck cancer microenvironment: Single-cell and spatial transcriptomics Yun Hak Kim (Pusan National University, Korea)

Scientific Symposium 1 (SS01)

Optimizing the transition to palliative care: Prognostic estimation and communication in oncology

Date & Time	Sep. 4 (Thu), 08:40-10:10	Venue	Room D (Walker Hall 2)
Chair(s)	Jin Hyuk Choi (Ajou University Hospital, Korea) Eileen Poon (National Cancer Centre Singapore, Singapore)
Session Details	1. Prognostic estimation for optimal timing of palliative care referrals: From classic to novel Yusuke Hiratsuka (Takeda General Hospital, Japan) 2. Designing structured approaches for prognostic communication and goal of care discussions Young Kwang Chae (Northwestern University, USA) 3. Real world challenges in shared decision-making: Integrating information and values Beodeul Kang (CHA Bundang Medical Center, Korea) 4. Training oncologists in prognostic estimation and communication: Building essential skills for clinical practice Eun Mi Nam (Ewha Womans University Seoul Hospital, Korea)

Satellite Symposium 1 (SL01)

Amivantamab combination: Combined power to change the game in NSCLC

Date & Time	Sep. 4 (Thu), 08:40-9:20	Venue	Room E (Grand Hall 4)
Chair(s)	Young Joo Min (Ulsan University Hospital, Korea)
Session Details	MARIPOSA: Combined power to change the game in EGFR+ NSCLC Beung-Chul Ahn (National Cancer Center, Korea)

Satellite Symposium 2 (SL02)

Clinical values of Lorviqua(Lorlatinib) as a 1st line treatment for ALK positive mNSCLC patients

Date & Time	Sep. 4 (Thu), 9:30-10:10	Venue	Room E (Grand Hall 4)
Chair(s)	Dae-ho Lee (Asan Medical Center, Korea)
Session Details	Redefining first-line standards: Lorlatinib in ALK+ mNSCLC Sun Min Lim(Yonsei University College of Medicine, Korea )

Plenary Lecture 1 (PL01)

Breaking new ground: Innovative cancer vaccine therapies

Date & Time	Sep. 4 (Thu), 10:40-11:20	Venue	Room A (Vista Hall 1)
Chair(s)	Joon Oh Park (Samsung Medical Center, Korea)
Session Details	Breaking new ground: Innovative cancer vaccine therapies Patrick Ott (Dana-Farber Cancer Institute, USA)

Luncheon Symposium 1 (LS01)

Keytruda in HER2+ and HER2– gastric Cancer : Recent updates and real-world insights from KN811 & KN859

Date & Time	Sep. 4 (Thu), 11:30-12:10	Venue	Room A (Vista Hall 1)
Chair(s)	Min-hee Ryu (Asan Medical Center, Korea)
Session Details	Keytruda in HER2+ and HER2– gastric Cancer : Recent updates and real-world insights from KN811 & KN859 Seok Jae Huh (Dong-A University College of Medicine, Korea)

Luncheon Symposium 2 (LS02)

Confirmed efficacy data of Verzenio for high-risk EBC patients: MonarchE updates and 2yrs patient journey

Date & Time	Sep. 4 (Thu), 11:30-12:10	Venue	Room B (Vista Hall 3)
Chair(s)	Joohyuk Sohn (Yonsei Cancer Hospital, Korea)
Session Details	Confirmed efficacy data of Verzenio for high-risk EBC patients : MonarchE updates and 2yrs patient journey Junghoon Shin (Samsung Medical Center, Korea)

Luncheon Symposium 3 (LS03)

FLAURA2: Advancing first-line therapy for patients with EGFRm NSCLC

Date & Time	Sep. 4 (Thu), 11:30-12:10	Venue	Room C (Walker Hall 1)
Chair(s)	Ki Hyeong Lee (Chungbuk National University Hospital, Korea)
Session Details	FLAURA2: Advancing First-Line Therapy for Patients with EGFRm NSCLC Hye Ryun Kim (Yonsei Cancer Center, Korea)

Luncheon Symposium 4 (LS04)

Expanding the Horizon of HER2 Therapy: ADC Treatment for breast cancer patients across HER2 expression spectrum

Date & Time	Sep. 4 (Thu), 11:30-12:10	Venue	Room D (Walker Hall 2)
Chair(s)	Jee Hyun Kim (Seoul National University Bundang Hospital, Korea)
Session Details	Expanding the horizon of HER2 therapy: ADC treatment for breast cancer patients across HER2 expression spectrum Heejung Chae (Seoul National University Bundang Hospital, Korea)

Luncheon Symposium 5 (LS05)

EGFRm+ NSCLC

Date & Time	Sep. 4 (Thu), 11:30-12:10	Venue	Room E (Grand Hall 4)
Chair(s)	Ji-Youn Han (National Cancer Center, Korea)
Session Details	The LASER effect : Lazertinib's rise as a new SoC in EGFRm+ NSCLC 1L treatment Jinyong Kim (Samsung Medical Center, Korea)

Scientific Symposium 2 (SS02)

Revolutionizing GI cancer care with next-generation modalities

Date & Time	Sep. 4 (Thu), 12:20-13:50	Venue	Room A (Vista Hall 1)
Chair(s)	Sang-Cheol Lee (Soonchunhyang University Hospital, Korea) Jin Li (Shanghai East Hospital, China)
Session Details	1. CLDN18.2: New target for gastric and pancreatic cancer Zev A. Weinberg (UCLA, USA) 2. Novel IO combinations for GI cancers: Beyond PD-1/PD-L1 and CTLA4 Minsuk Kwon (Samsung Medical Center, Korea) 3. Emerging cell-based therapy for GI cancers Changsong Qi (Peking University Cancer Hospital and Institute, China) 4. Novel therapeutic vaccine for GI cancers Tetsuya Nakatsura (National Cancer Center, Japan)

Education Session 3 (ES03)

Cancer survivorship: Shifting paradigms in care KOREAN

Date & Time	Sep. 4 (Thu), 12:20-13:50	Venue	Room B (Vista Hall 3)
Chair(s)	Gyeong-Won Lee (Gyeongsang National University, Korea) Soon Nam Lee (Ewha Womans University Mokdong Hospital, Korea)
Session Details	1. Surviving with emerging long-term toxicities Yun-Gyoo Lee (Kangbuk Samsung Hospital, Korea) 2. Genetic counseling for cancer survivors Ji Soo Park (Cancer Prevention Center, Yonsei Cancer Center, Korea) 3. Restoring emotional strength after cancer: Psychological interventions Seockhoon Chung (Asan Medical Center, Korea) 4. Empowered survivorship through digital health Juhee Cho (Samsung Comprehensive Cancer Center, Korea)

Scientific Symposium 3 (SS03)

How shall we treat RARE cancer in the era of precision medicine : Progress and challenges ahead

Date & Time	Sep. 4 (Thu), 12:20-13:50	Venue	Room C (Walker Hall 1)
Chair(s)	Eun Mi Nam (Ewha Womans University Seoul Hospital, Korea) Jen-Shi Chen (Linkou Chang Gung Memorial Hospital, Taiwan)
Session Details	1. How can we facilitate personalized trial for rare cancers: KCSG experience Bhumsuk Keam (Seoul National University Hospital, Korea) 2. Role of (pre)clinical trials in rare cancer: Focusing on adenoid cystic carcinoma Hyunseok Kang (UCSF, USA) 3. METRNL cytokine drives immune cell exhaustion in tumor infiltrating lymphocytes by inducing bioenergic dysregulation Michael Lim (Standford University, USA) 4. Advancing Glioblastoma therapy through proteogenomic integration Jong Bae Park (National Cancer Center, Korea)

KOSRO/KSMO Joint Symposium 3 (JS03)

Optimization of neoadjuvant/adjuvant treatment

Date & Time	Sep. 4 (Thu), 12:20-13:50	Venue	Room D (Walker Hall 2)
Chair(s)	Hak Jae Kim (Seoul National University Hospital, Korea) Sang Cheul Oh (Korea University Guro Hospital, Korea)
Session Details	1. Optimization of adjuvant radiotherapy in breast cancer Bruno Meduri (Azienda Provinciale per i Servizi Sanitari (APSS), Italy) 2. Reassessing neoadjuvant therapy in locally advanced rectal cancer: Insights from the PROSPECT trial and other recent and ongoing trials Deborah Schrag (Memorial Sloan Kettering Cancer Center, USA) 3. NSCLC neoadjuvant regimen Jang Ho Cho (Gachon University Gil Medical Center, Korea) 4. Radiotherapy for sacroma: Overcoming traditional perceptions and exploring future directions Jeong Il Yu (Samsung Medical Center, Korea)

Satellite Symposium 3 (SL03)

Pembrolizumab, rewriting the treatment paradigm in 1L endometrial cancer

Date & Time	Sep. 4 (Thu), 12:20-13:00	Venue	Room E (Grand Hall 4)
Chair(s)	Gun Min Kim (Yonsei Cancer Hospital, Korea)
Session Details	Pembrolizumab, rewriting the treatment paradigm in 1L endometrial cancer In Hee Lee (Kyungpook National University Chilgok Hospital, Korea)

Satellite Symposium 4 (SL04)

Bridging VISION to reality: Clinical insights into PSMA RLT adoption

Date & Time	Sep. 4 (Thu), 13:10-13:50	Venue	Room E (Grand Hall 4)
Chair(s)	Keon-Uk Park (Keimyung University Dongsan medical Center, Korea)
Session Details	Bridging VISION to reality: Clinical insights into PSMA RLT adoption Inkeun Park (Asan Medical Center, Korea)

ESMO/KSMO Joint Symposium 4 (JS04)

ESMO guideline and the implementation in Asian Pacific region

Date & Time	Sep. 4 (Thu), 14:00-15:30	Venue	Room A (Vista Hall 1)
Chair(s)	Myung Ah Lee (KSMO 2025 Chair, The Catholic University of Korea Seoul St. Mary’s Hospital, Korea) Fabrice André (ESMO President, Gustave Roussy, Villejuif, France)
Session Details	1. Case presentation Kyung-Hun Lee (Seoul National University Hospital, Korea) 2. Critical analysis and presentation of the ESMO guideline early breast cancer, with MCBS and ESCAT Fabrice André (Gustave Roussy, Villejuif, France) 3. Asian perspectives on genetics, practice, and applicability of ESMO guideline in early breast cancer Jee Hyun Kim (Seoul National University Bundang Hospital, Korea) 4. Case presentation Inkeun Park (Asan Medical Center, Korea) 5. Critical analysis and presentation of the ESMO Guideline - Kidney cancer, with ESMO-MCBS Matthew Young (Barts Cancer Institute, Queen Mary University of London, UK) 6. Challenges and solutions for implementing ESMO renal cell carcinoma treatment guidelines in Korea Jae Lyun Lee (Asan Medical Center, Korea)

KSSO/KSMO Joint Symposium 5 (JS05)

Omit surgery in GI cancer treatment

Date & Time	Sep. 4 (Thu), 14:00-15:30	Venue	Room B (Vista Hall 3)
Chair(s)	Joong Bae Ahn (Yonsei University College of Medicine, Korea) Naru Kim (Ewha Womans University College of Medicine, Korea)
Session Details	1. Omitting surgery in pancreatic cancer: Can systemic therapy alone replace resection? Kosuke Kobayashi (Cancer Institute Hospital, Japan) 2. Omit surgery in rectal cancer: Is watch-and-wait a viable long-term strategy? Minsu Kang (Seoul National University Bundang Hospital, Korea) 3. Omit surgery in gastric cancer: When can we rely on non-surgical therapy alone? Jaemin Jo (Jeju National University Hospital, Korea) 4. Local therapies vs surgery in hepatocellular carcinoma: Is resection always necessary? Kenneth Chok (The Chinese University of Hong Kong, Hong Kong)

Education Session 4 (ES04)

Toxicity management in Antibody-Drug Conjugates (ADCs) KOREAN

Date & Time	Sep. 4 (Thu), 14:00-15:30	Venue	Room C (Walker Hall 1)
Chair(s)	Jong Gwang Kim (Kyungpook National University Chilgok Hospital, Korea) Kyoung Eun Lee (Ewha Women's University Hospital, Korea)
Session Details	1. Structural and functional drivers of ADC toxicity In Hae Park (Korea University Guro Hospital, Korea) 2. Overview of toxicities of ADCs (including hematologic toxicities) Han Jo Kim (Soonchunhyang University Cheonan Hospital, Korea) 3. Pulmonary toxicities from ADCs Jimyung Park (Seoul National University Hospital, Korea) 4. Ocular toxicities from ADCs Chang Ho Yoon (Seoul National University Hospital, Korea)

Scientific Symposium 4 (SS04)

Current trends and future perspectives in GU oncology

For the scientific session on genitourinary cancers, we have prepared a series of in-depth lectures under the theme “Current Trends and Future Perspectives in GU Oncology,” covering four highly topical subjects. From the United States, Dr. Ramaprasad Srinivasan from the National Cancer Institute—renowned for his leading work in hereditary kidney cancer and non-clear cell renal cell carcinoma—will present on "Mechanism-Based Treatment Strategies in RCC." Dr. David Brown from Yale School of Medicine, an active researcher in biomarkers for renal cell carcinoma, will deliver a talk entitled "Biomarkers in RCC: Current Status and Future Direction." From Korea, Professor Hyunsoo Lim of Ulsan University Hospital will speak on "Antibody-Drug Conjugates in Advanced Urothelial Carcinoma: Established & Emerging Drugs," while Professor Hyunho Kim of St. Vincent’s Hospital will discuss "How Can We Integrate PARP Inhibitors in the Treatment of Prostate Cancer?" This session is expected to provide an excellent opportunity to explore and discuss the latest insights into some of the most compelling and rapidly evolving topics in the field of genitourinary oncology.

비뇨기암 (genitourinary cancers)에서의 Scientific Session에서는 "Current trends and future perspectives in GU oncology."라는 테마로 최근 화제가 되고 있는 4개의 주제에 대해 매우 심도있는 강의를 준비하였습니다. 국제연자로는 NCI에서 유전성 신장암과 비투명세포신장암에서 많은 연구과 약제개발을 주도하는 Ramaprasad Srinivasan이 "Mechanism-based treatment strategies in RCC"를, Yale school of Medicine에서 신장암 바이오마커 관련한 연구를 활발히 하고 있는 David Brown이 "Biomarkers in RCC: current status and future direction"를 발표할 것입니다. 또한 국내연자로는 울산대병원 임현수 교수가 "Antibody-drug conjugate in advanced urothelial carcinoma: Established & emerging drugs"를, 성빈센트 병원 김현호 교수가 "How can we integrate PARP inhibitors in treatment of prostate cancer?"를 발표하여, 다양한 비뇨기암의 가장 핫한 토픽에 대한 최신지견을 듣고 논의하는 자리가 될 것으로 기대합니다.

Date & Time	Sep. 4 (Thu), 14:00-15:30	Venue	Room D (Walker Hall 2)
Chair(s)	Hyun Woo Lee (Ajou University Hospital, Korea) James Lynam (Calvary Mater Hospital, Australia)
Session Details	1. Mechanism-based treatment strategies in RCC Ramaprasad Srinivasan (National Cancer Institute, USA) 2. Biomarkers in RCC: Current status and future direction David Braun (Yale School of Medicine, USA) 3. Antibody-drug conjugate in advanced urothelial carcinoma: Established & emerging drugs Hyeon-Su Im (Ulsan University Hospital, Korea) 4. How can we integrate PARP inhibitors in treatment of prostate cancer? Hyunho Kim (The Catholic University of Korea St. Vincent's Hospital, Korea)

Satellite Symposium 5 (SL05)

Advances and innovations in ES-SCLC treatment

Date & Time	Sep. 4 (Thu), 14:00-14:40	Venue	Room E (Grand Hall 4)
Chair(s)	Jong Mu Sun (Samsung Medical Center, Korea)
Session Details	Targeting DLL3 with BiTE therapy: A new paradigm in SCLC treatment Jeonghwan Youk(Seoul National University Hospital, Korea)

Satellite Symposium 6 (SL06)

Optimizing HCC treatment sequence

Date & Time	Sep. 4 (Thu), 14:50-15:30	Venue	Room E (Grand Hall 4)
Chair(s)	Hong Jae Chon (Cha Bundang Medical Center, Korea)
Session Details	Optimal continuum of care for advanced hepatocellular carcinoma in the era of first-line immunotherapy Changhoon Yoo (Asan Medical Center, Korea)

Plenary Lecture 2 (PL02)

Cancer cachexia: Transition from science to practice

Date & Time	Sep. 4 (Thu), 15:40-16:20	Venue	Room A (Vista Hall 1)
Chair(s)	Kyung Hee Lee (Yeungnam University, Korea)
Session Details	Cancer cachexia: Transition from science to practice Jeffrey Crawford (Duke Cancer Institute, USA)

Scientific Symposium 5 (SS05)

Current Insights and future directions of MBC treatment

Date & Time	Sep. 4 (Thu), 16:20-17:50	Venue	Room A (Vista Hall 1)
Chair(s)	Seock-Ah Im (Seoul National University Hospital, Korea) Janice Tsang (The University of Hong Kong, Hong Kong)
Session Details	1. Targeting PTEN/PI3K/AKT pathway: Roles and limitations Carlos Arteaga (UT Southwestern Harold C. Simmons Cancer Center, USA) 2. Optimizing anti-Her2 treatment in the era of ADCs Jieun Park (Jeju National University Hospital, Korea) 3. Cutting-edge advances in TNBC: Beyond immunotherapy Kyong Hwa Park (Korea University Anam Hospital, Korea) 4. Managing oligometastasis- Is it curable? Gun Min Kim (Yonsei University College of Medicine, Korea)

Oral Presentation 1 (OP01)

Date & Time	Sep. 4 (Thu), 16:20-17:20	Venue	Room B (Vista Hall 3)
Chair(s)	Se Hyun Kim (Seoul National University Bundang Hospital, Korea) Yeesoo Chae (Kyungpook National University Medical Center, Korea)
Session Details	1. Demographic and clinical predictors of survival among patients with second malignant neoplasms following primary tongue cancer: A population-based study Ahmed Elkoumi (Egyptian Russian University, Egypt) 2. Clinical effect of bisphosphonate in patients with hormone receptor-positive early breast cancer: A nationwide real-world data analysis WonSeok Choi (Korea University Guro Hospital, Korea) 3. Association between genomic features and radiation response in metastatic breast cancer patients undergoing palliative radiotherapy Hyeon Seok Choi (Seoul National University College of Medicine, Korea) 4. The impact of brain MRI surveillance on survival outcomes in initially CNS metastasis-free non-small cell lung cancer Seong-Eun Kim (Asan Medical Center, Korea) 5. Durvalumab-based treatment for recurrent or metastatic pulmonary sarcomatoid carcinoma: Pooled analysis of two KCSG trials Dong Hyun Kim (Seoul National University Hospital, Korea) 6. Evaluating immunotherapy outcomes in elderly patients with extensive-stage small-cell lung cancer (KCSG LU23-15) Yun-Gyoo Lee (Kangbuk Samsung Hospital, Korea)

Poster Discussion 1 (PD01)

Date & Time	Sep. 4 (Thu), 17:20-17:50	Venue	Exhibition Hall (Grand Hall, B1)
Chair(s)	Kyung-Hun Lee (Seoul National University Hospital, Korea)
Session Details	1. Safety and efficacy evaluation of XP and Herzuma® combination chemotherapy for the first-line treatment of advanced gastric or GE junction adenocarcinoma patients Hye Ryeon Kim (Dong-A University Hospital, Korea) 2. Third- and fourth-line trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer: Does timing and combination matter? Dong-Hoe Koo (Kangbuk Samsung Medical Center, Korea) 3. Quantitative circulating DNA (ctDNA) analysis for determination of chemotherapy in advanced colorectal cancer: Pilot study Myung Ah Lee (The Catholic University of Korea Seoul St. Mary’s Hospital, Korea) 4. Development and evaluation of a highly sensitive multiplex MSI assay for five mononucleotide markers on real-time and digital PCR platforms Kyeong Hwangbo (Seasun Biomaterials, Korea) 5. Efficacy and safety of netupitantpalonosetron in colorectal cancer patients receiving moderate-emetogenic chemotherapy: An interim analysis Monson Saritwetworakun (Siriaj Hospital, Thailand)

Scientific Symposium 6 (SS06)

Clinical promise of ctDNA-based MRD testing in solid tumors

At KSMO 2025, we are pleased to present a dedicated Scientific Session on Minimal Residual Disease (MRD)—a rapidly emerging focus in the management of solid tumors. Liquid biopsy–based MRD analysis has demonstrated superior prognostic value over conventional clinical factors in multiple large-scale prospective and retrospective studies in recent years. Reflecting this growing evidence base, the 2025 updates to the NCCN Guidelines have, for the first time, incorporated MRD in the management of B-cell lymphomas, colorectal cancer, and Merkel cell carcinoma. This marks a pivotal moment, signaling the beginning of broader clinical integration of MRD in routine oncology practice. In this session, we aim to share the latest developments in MRD research with both domestic and international experts, and to explore the key challenges that must be addressed to enable its wider clinical application. To that end, we have invited three of the world’s leading authorities in MRD research, each representing a critical domain of advancement:
• Dr. Yongjun Cha (IMBdx, Inc., Korea) – Introduction for MRD in solid tumors
• Prof. Aadel Chaudhuri (Mayo Clinic, USA) – Technological advancements in MRD
• Prof. Takayuki Yoshino (National Cancer Center East, Japan) – Clinical insights from CIRCULATE-Japan
• Prof. Aparna Parikh (Massachusetts General Hospital, USA) – MRD-driven clinical trials and drug development
MRD is poised to become an indispensable element in the treatment and clinical investigation of locally advanced solid tumors. We hope this session will provide all participants of KSMO 2025 with valuable insights into the future of MRD, as well as rare opportunities to learn directly from global leaders in the field.

KSMO 2025에서는 최근 고형암 분야에서 가장 주목받고 있는 주제 중 하나인 미세잔존암(Minimal Residual Disease, MRD)을 중심으로 한 Scientific Session을 준비했습니다. 액체생검 기반의 MRD 분석은 지난 수년간 다수의 전향적 및 후향적 대규모 연구를 통해 기존의 어떠한 예후인자보다도 강력한 임상적 의의를 갖는 것으로 입증되어 왔습니다. 이러한 근거를 바탕으로, MRD는 2025년 개정된 NCCN 가이드라인(림프종, 대장암, 메르켈세포암 등)에 처음으로 공식 등재되었으며, 이는 MRD의 임상적 적용이 이제 본격적인 확산의 전환점을 맞이했음을 시사합니다. 본 세션에서는 MRD 연구의 최신 동향을 국내외 전문가들과 공유하고, 실제 임상 적용 확대를 위해 해결해야 할 기술적·임상적 과제들을 함께 논의하고자 합니다. 이를 위해, 각각의 주요 분야를 대표하는 세계적인 연구자들을 연자로 모셨습니다:
• Yongjun Cha (IMBdx, Korea) – 고형암에서 MRD 기술의 개괄
• Aadel Chaudhuri 교수 (Mayo Clinic, USA) – MRD 기술의 진보와 혁신
• Takayuki Yoshino 교수 (National Cancer Center East, Japan) – CIRCULATE-Japan 연구로 보는 MRD의 임상적 활용
• Aparna Parikh 교수 (Massachusetts General Hospital, USA) – MRD 기반 임상시험 및 신약개발 전략
MRD는 향후 국소 진행성 고형암의 치료 전략뿐 아니라 임상시험 디자인과 신약개발에서도 핵심적인 역할을 할 것으로 기대됩니다. 본 세션이 KSMO 2025에 참석하시는 국내외 연구자들에게 MRD 분야에 대한 통찰과 실질적인 아이디어를 제공하는 뜻깊은 자리가 되기를 바랍니다.

Date & Time	Sep. 4 (Thu), 16:20-17:50	Venue	Room C (Walker Hall 1)
Chair(s)	Tae-You Kim (Seoul National University Hospital, Korea) Tubagus Djumhana Atmakusuma (Indonesian Society of Hematology Medical Oncology, Indonesia)
Session Details	1. ctDNA MRD for solid tumors: Translating clinical evidence into practice Yongjun Cha (IMB Dx, Korea) 2. ctDNA MRD for solid tumors: Overcoming technical challenges for broader clinical implementation Aadel Chaudhuri (Mayo Clinic, USA) 3. Striving for a quantum leap on Molecular Residual Disease (MRD) clinical development: Insights from CIRCULATE-JAPAN & SCRUM- MONSTAR Takayuki Yoshino (National Cancer Center Hospital East, Japan) 4. Leveraging ctDNA MRD in clinical trials and drug development: Opportunities and outlook Aparna Parikh (Massachusetts General Hospital, USA)

KSR/KSMO Joint Symposium 6 (JS06)

Radiomics Revolution: AI and imaging in cancer care

Date & Time	Sep. 4 (Thu), 16:20-17:50	Venue	Room D (Walker Hall 2)
Chair(s)	Ho Sung Kim (Asan Medical Center, Korea) Joung Soon Jang (Chung-ang University Hospital, Korea)
Session Details	1. The prognostic role of CT-determined sarcopenia in cancer treatment outcomes Young Saing Kim (Gachon University Gil Medical Center, Korea) 2. Using CT-derived body composition indices to predict CDK4/6 inhibitor response in breast cancer patients Min Hwan Kim (Yonsei Cancer Center, Korea) 3. Radiomics and AI in lung cancer assessment Guillaume Chassagnon (Université Paris Cité, France) 4. Radiomics and AI in neuro-oncology Sung Soo Ahn (Yonsei University College of Medicine, Korea)

Satellite Symposium 7 (SL07)

Optimizing outcomes with Cabometyx in patients with mRCC considering latest changes in treatment sequence

Date & Time	Sep. 4 (Thu), 16:20-17:00	Venue	Room E (Grand Hall 4)
Chair(s)	Woo Kyun Bae (Chonnam National University Hwasun Hospital, Korea)
Session Details	Optimizing outcomes with Cabometyx in patients with mRCC considering latest changes in treatment sequence Chang Gon Kim (Yonsei Cancer Center, Korea)

Satellite Symposium 8 (SL08)

Later-line treatment for metastatic colorectal cancer focusing on FTD/TPI

Date & Time	Sep. 4 (Thu), 17:10-17:50	Venue	Room E (Grand Hall 4)
Chair(s)	Seung Tae Kim (Samsung Medical Center, Korea)
Session Details	Later-line treatment for metastatic colorectal cancer focusing on FTD/TPI Jwa Hoon Kim (Korea University Anam Hospital, Korea)

Sep. 5 (Fri)

JSMO/KSMO Joint Symposium 7 (JS07)

The new standard therapy in solid tumors : The combination of immunotherapies

Date & Time	Sep. 5 (Fri), 08:40-10:10	Venue	Room A (Vista Hall 1)
Chair(s)	Baek-Yeol Ryoo (KSMO Chair of General Assembly, Asan Medical Center, Korea) Hironobu Minami (JSMO President, Kobe University, Japan)
Session Details	1. Frontline therapy in MSI-H metastatic colorectal cancer Junho Lee (Kyung Hee University Hospital, Korea) 2. Frontline therapy in metastatic hepatocellular carcinoma Hong sik Kim (Chungbuk National University Hospital, Korea) 3. Adjuvant and neoadjuvant therapy for melanoma in East Asia Kenjiro Namikawa (National Cancer Center Hospital, Tokyo, Japan) 4. Preoperative and frontline therapy in breast cancer (TNBC) Kenji Tamura (Shimane University Hospital, Japan)

Education Session 5 (ES05)

Advance of technology - Artificial intelligence in oncology KOREAN

Date & Time	Sep. 5 (Fri), 08:40-10:10	Venue	Room B (Vista Hall 3)
Chair(s)	Sang-Hee Cho (Chonnam National University Hwasun Hospital, Korea)
Session Details	1. Introduction: Artificial intelligence in oncology Chanyoung Ock (Lunit, Korea) 2. Clinical application of radiology-based AI model for breast cancer: Current and future Eunkyung Kim (Yonsei University College of Medicine, Korea) 3. Clinical application of pathology-based AI model: Current and future Yoon Jin Cha (Gangnam Severance Hospital, Korea) 4. LLM based medical research Jeong Moo Lee (Seoul National University Hospital, Korea)

Scientific Symposium 7 (SS07)

Novel opportunities to target cancer: Emerging strategies in molecular oncology

Date & Time	Sep. 5 (Fri), 08:40-10:10	Venue	Room C (Walker Hall 1)
Chair(s)	Do-Youn Oh (Seoul National University Hospital, Korea) Sang Joon Shin (Yonsei University College of Medicine, Korea)
Session Details	1. Exploring the cell death phenotypic landscape for cancer Scott J. Dixon (Stanford University, USA) 2. Repurposing cardiac drugs beta-blockers for cancer treatment Erica Sloan (Monash University, Australia) 3. Targeting metastatic cancer via synthetic lethality Mi-Young Kim (KAIST, Korea) 4. Research and commercial activities in low earth orbit for cancer therapeutics Hargsoon Yoon (Norfolk State University, USA)

KSP/KSMO Joint Symposium 8 (JS08)

Biomarker for ADC

Date & Time	Sep. 5 (Fri), 08:40-10:10	Venue	Room D (Walker Hall 2)
Chair(s)	Sang Cheul Oh (Korea University Guro Hospital, Korea) Gian Franco Zannoni (Università Cattolica del Sacro Cuore, Italy)
Session Details	1. Companion diagnostics update and future strategy for oncology Jan Trøst Jørgensen (Dx-Rx Institute, Fredensborg, Denmark) 2. Biomakrer development for ADC Yoon-La Choi (Samsung Medical Center, Korea) 3. Recent optimization of ADC CDx : FOLR1 IHC Gian Franco Zannoni(Università Cattolica del Sacro Cuore, Italy) 4. Application of AI for biomarker interpretation Tae-Yeong Kwak (Deep Bio Inc., Korea)

Satellite Symposium 9 (SL09)

Paradigm shift in the treatment of mCRC: Unveiling the potential of FRUZAQLA

Date & Time	Sep. 5 (Fri), 08:40-9:20	Venue	Room E (Grand Hall 4)
Chair(s)	Seung Hoon Beom (Yonsei Cancer Hospital, Korea)
Session Details	Paradigm shift in the treatment of mCRC: Unveiling the potential of FRUZAQLA Takayuki Yoshino (National Cancer Center Hospital East, Japan)

Satellite Symposium 10 (SL10)

Recent clinical data and real-world case updates on Opdivo in gastric cancer first-line treatment

Date & Time	Sep. 5 (Fri), 09:30-10:10	Venue	Room E (Grand Hall 4)
Chair(s)	Keun-Wook Lee (Seoul National University Bundang Hospital, Korea)
Session Details	Recent clinical data and real-world application of opdivo in the first-line setting for gastric cancer Jaewon Hyung (Asan Medical Center, Korea)

Plenary Lecture 3 (PL03)

Advances in chemotherapy for gastric cancer- Future perspectives

Date & Time	Sep. 5 (Fri), 10:30-11:10	Venue	Room A (Vista Hall 1)
Chair(s)	Sun Young Rha (Yonsei University College of Medicine, Korea)
Session Details	Advances in chemotherapy for gastric cancer- Future perspectives Kohei Shitara (National Cancer Center Hospital East, Japan)

Luncheon Symposium 6 (LS06)

Innovative SCLC treatment approaches

Date & Time	Sep. 5 (Fri), 11:30-12:10	Venue	Room A (Vista Hall 1)
Chair(s)	Young-Woong Won (Hanyang University Guri Hospital, Korea)
Session Details	Advancing SCLC management with Lurbinectedin clinical experience and IMforte study innovations Taehwan Kim (Ajou University School of Medicine, Korea)

Luncheon Symposium 7 (LS07)

From mTNBC to HR+/HER2- mBC: Sacituzumab Govetican leads the way with proven survival benefit

Date & Time	Sep. 5 (Fri), 11:30-12:10	Venue	Room B (Vista Hall 3)
Chair(s)	Kyong Hwa Park (Korea University ANAM Hospital, Korea)
Session Details	From mTNBC to HR+/HER2- mBC: Sacituzumab Govetican leads the way with proven survival benefit Dae-Won Lee (Seoul National University Hospital, Korea)

Luncheon Symposium 8 (LS08)

Game changer in GC treatment: New hope for CLDN18.2 positive patients

Date & Time	Sep. 5 (Fri), 11:30-12:10	Venue	Room C (Walker Hall 1)
Chair(s)	Seung Tae Kim (Samsung Medical Center, Korea)
Session Details	The breakthrough in gastric cancer: VYLOY new hope for CLDN18.2 positive patients Choong-kun Lee (Yonsei Cancer Center, Korea)

Luncheon Symposium 9 (LS09)

From NATALEE to practice: Shaping the new era of HR+/HER2- early breast cancer therapy

Date & Time	Sep. 5 (Fri), 11:30-12:10	Venue	Room D (Walker Hall 2)
Chair(s)	Yeon Hee Park (Samsung Medical Center, Korea)
Session Details	From NATALEE to practice: Shaping the new era of HR+/HER2- early breast cancer therapy Jee Hyun Kim (Seoul National University Bundang Hospital, Korea)

Luncheon Symposium 10 (LS10)

Personalized treatment to maximize outcomes for CCA : Focused on Ivosidenib

Date & Time	Sep. 5 (Fri), 11:30-12:10	Venue	Room E (Grand Hall 4)
Chair(s)	Hei Cheul Jeung (Gangnam Severance Cancer Hospital, Korea)
Session Details	Exploring long-term treatment outcomes with Ivosidenib in Cholangiocarcinoma Beodeul Kang (CHA Bundang Medical Center, Korea)

ASCO/KSMO Joint Symposium 9 (JS09)

The impact of NGS testing in oncology patients

Date & Time	Sep. 5 (Fri), 12:20-13:50	Venue	Room A (Vista Hall 1)
Chair(s)	Joon Oh Park (KSMO President, Samsung Medical Center) Elizabeth Mittendorf (ASCO President-Elect, Dana-Farber Cancer Institute, USA)
Session Details	1. NGS: Should all metastatic cancer patients receive NGS as part of practice: US perspectives Steve Maron (Memorial Sloan Kettering Cancer Center, USA) 2. NGS: Should all metastatic cancer patients receive NGS as part of practice: Korean perspectives Sung Hee Lim (Samsung Medical Center, Korea) 3. NGS benefits biliary tract cancer patients Haley Ellis (Massachusetts General Hospital, USA) 4. When rarity meets NGS : Unlocking hope for rare cancer patients Hyo song Kim (Yonsei University College of Medicine, Korea)

Oral Presentation 2 (OP02)

Date & Time	Sep. 5 (Fri), 12:20-13:20	Venue	Room B (Vista Hall 3)
Chair(s)	Tae-Yong Kim (Seoul National University Hospital, Korea) Dong-Hoe Koo (Kangbuk Samsung Hospital, Korea)
Session Details	1. A phase II clinical trial of Bevacizumab plus eRlotinIb in patients with advanced cancer having genetic alterations in the Krebs cycle (BRISK): KCSG AL22-16 Hyehyun Jung (Asan Medical Center, Korea) 2. Liposomal irinotecan with fluorouracil and leucovorin as salvage treatment for advanced biliary tract cancer refractory to gemcitabine and cisplatin Hyunho Kim (The Catholic University of Korea, ST. Vincent’s Hospital, Korea) 3. Referral timing for palliative care consultation and its associations with end-of-life outcomes in patients with cancer Jung Sun Kim (CHA University Bundang Medical Center, Korea) 4. Prognostic significance of PTEN gene mutations and loss of expression in colorectal cancer Asgar Ali (All India Institute of Medical Sciences Patna, India) 5. Prognostic impacts of FGFR2b and genetic variation in patients with poorly cohesive cells gastric cancer Yunji Lee (Kyungpook National University Chilgok Hospital, Korea) 6. Favorable outcomes of EBV-associated gastric cancer treated with first-line immunotherapy plus chemotherapy: A multicenter real-world study In-Ho Kim (The Catholic Univ. of Korea Seoul St.Mary's Hospital, Korea)

Poster Discussion 2 (PD02)

Date & Time	Sep. 5 (Fri), 13:20-13:50	Venue	Exhibition Hall (Grand Hall, B1)
Chair(s)	In Gyu Hwang (Chung-Ang University Hospital, Korea)
Session Details	1. Preoperative axillary ultrasound to detect lymph node metastasis in early breast cancer, a prospective trial Siriporn Bureewong (Abhaibhubejh Hospital, Thailand) 2. Rapid and convenient fluoroimmunoassay using recombinant antibody against HER2 Hyeon-Min Yang (Hongik University, Korea) 3. Integrative analysis of 26,848 human transcriptomes reveals cancer-specific isoform dysregulation at the full-length transcript resolution Junghoon Shin (Samsung Medical Center, Korea) 4. Predictive role of co-occuring genomic alterations on survival outcomes of first-line osimertinib treatment in patients with EGFR mutant non-small-cell lung cancer Seong-Eun Kim (Asan Medical Center, Korea) 5. Development of a blood-based digital PCR assay using novel DNA methylation biomarkers for detecting early lung cancer Jin Soo Kim (Seoul Metropolitan Government Seoul National University Boramae Medical Center, Korea)

Multi-Disciplinary Case Discussion (MDCD)

Personalized treatment strategies for oligometastatic patients in the new era of cancer therapeutics KOREAN

Date & Time	Sep. 5 (Fri), 12:20-13:50	Venue	Room C (Walker Hall 1)
Chair(s)	Kyubo Kim (Seoul National University Bundang Hospital, Korea) Sung Yong Oh (Donga University Hospital, Korea)
Session Details	1. LCT and the possibility of cure in oligometastatic NSCLC: For whom, and to what extent? Chai Hong Rim (Korea University College of Medicine, Korea) 2. Integrating local and systemic therapies for oligometastatic patients in the new era of novel cancer treatments In Hee Lee (Kyungpook National University Chilgok Hospital, Korea) 3. Biomarkers in oligometastasis: Current insights and future directions Dae-Won Lee (Seoul National University College of Medicine, Korea) 4. Spine SBRT Hwa Kyung Byun (Yongin Severance Hospital, Korea)

Scientific Symposium 8 (SS08)

Combinatory strategy to enhance immune checkpoint response

Date & Time	Sep. 5 (Fri), 12:20-13:50	Venue	Room D (Walker Hall 2)
Chair(s)	Tae Min Kim (Seoul National University Hospital, Korea) Smruti Koppikar(Indian Society of Medical and Pediatric Oncology, India)
Session Details	1. Optimal immunotherapy combination strategies for hepatobiliary cancer Changhoon Yoo (Asan Medical Center, Korea) 2. Recent advances of bispecific antibody for cancer immunotherapy Sangmi Lee (ABL Bio., Korea) 3. Novel ADCs and immune modulating agents to overcome immunotherapy resistance Toshio Shimizu (Kansai Medical University Hospital, Osaka, Japan) 4. Inducing anti-tumor immune response by radiation therapy Kyung Hwan Kim (Yonsei Cancer Center, Korea)

Satellite Symposium 11 (SL11)

New horizons in nausea and vomiting: Rethinking MEC strategies

Date & Time	Sep. 5 (Fri), 12:20-13:00	Venue	Room E (Grand Hall 4)
Chair(s)	Jung Hye Kwon (Chung-Ang University Gwangmyeong Hospital, Korea)
Session Details	New horizons in nausea and vomiting: Rethinking MEC strategies Karin Jordan (Klinikum Ernst von Bergmann Potsdam, Germany)

Satellite Symposium 12 (SL12)

From data to practice: Redefining the standard of care for patients with advanced UC

Date & Time	Sep. 5 (Fri), 13:10-13:50	Venue	Room E (Grand Hall 4)
Chair(s)	Hyo-Jin Lee (Chungnam National University Hospital, Korea)
Session Details	From data to practice: Redefining the standard of care for patients with advanced UC Minsuk Kwon (Samsung Medical Center, Korea)

Plenary Lecture 4 (PL04)

Biomarkers to predict efficacy and toxicity of antibody drug conjugates in breast cancer

Date & Time	Sep. 5 (Fri), 14:00-14:40	Venue	Room A (Vista Hall 1)
Chair(s)	Sung-bae Kim (Asan Medical Center, Korea)
Session Details	Biomarkers to predict efficacy and toxicity of antibody drug conjugates in breast cancer Giuseppe Curigliano (European Institute of Oncology, IRCCS and Università degli Studi di Milano, Italy)

ESMO/KSMO Joint Symposium 10 (JS10)

How to streamline initiatives for optimising oncology practice

Date & Time	Sep. 5 (Fri), 14:50-16:20	Venue	Room A (Vista Hall 1)
Chair(s)	Dong-Wan Kim (KSMO President-Elect, Seoul National University Hospital, Korea) Fabrice André (ESMO President, Gustave Roussy, Villejuif, France)
Session Details	1. ESMO ETAC-Tumour agnostic oncology: Drug development trends and mindsets Fernanda Mosele (Gustave Roussy, France) 2. “Asian” perspectives on drug development challenges and breakthroughs Sang Joon Shin (Yonsei Cancer Center, Korea) 3. Generative AI for treatment decisions Titus Brinker (German Cancer Research Center, Germany) 4. Generative AI and clinical decision support system utility in the hospital Wonchul Cha (Samsung Medical Center, Korea)

Scientific Symposium 9 (SS09)

Real-world challenges in GI oncology: Navigating complex treatment decisions

Date & Time	Sep. 5 (Fri), 14:50-16:20	Venue	Room C (Walker Hall 1)
Chair(s)	Ho Yeong Lim (CHA Bundang Medical Center, Korea) Koji Kono (Fukushima Medical University, Japan)
Session Details	1. How can we adopt immunotherapy for MSS CRC? Hyun Jin Bang (Chonnam National University Hwasun Hospital, Korea) 2. Systemic treatment strategies for HCC with poor liver function Sadahisa Ogasawara (Chiba University, Japan) 3. Who benefits from neoadjuvant chemotherapy in resectable pancreatic cancer? Choong-kun Lee (Yonsei Cancer Center, Korea) 4. GI cancer with peritoneal metastasis: Molecular insights into a hard-to-treat disease entity Raghav Sundar (Yale School of Medicine, USA)

Scientific Symposium 10 (SS10)

Revealing immune response and resistance through spatial profiling of NSCLC microenvironment

Date & Time	Sep. 5 (Fri), 14:50-16:20	Venue	Room D (Walker Hall 2)
Chair(s)	Ji-Youn Han(National Cancer Center, Korea) Chita I. Nazal-Matunog (San Pedro Hospital of Davao City, Philippines)
Session Details	1. Overview of tumor microenvironment of lung cancer Jaemoon Koh (Seoul National University Hospital, Korea) 2. AI-assisted TIL analysis as predictive biomarker for ICI in NSCLC Mehrdad Rakaee (Institute for Cancer Research, Oslo University Hospital, Norway) 3. Revealing immune response and resistance through spatial profiling of NSCLC Antoine Italiano (DITEP, Gustave Roussy, France) 4. Mapping the tumor microenvironment: Spatial transcriptomics and network biology reveal novel drug targets in lung adenocarcinoma Ece D. Uzun (The Warren Alpert Medical School of Brown University, USA)

Satellite Symposium 13 (SL13)

Redefining PI3K pathway inhibitors in HR+ breast cancer with Inavolisib

Date & Time	Sep. 5 (Fri), 14:50-15:30	Venue	Room E (Grand Hall 4)
Chair(s)	Kyung Hae Jung (Asan Medical Center, Korea)
Session Details	Redefining PI3K pathway inhibitors in HR+ breast cancer with Inavolisib Seock-Ah Im (Seoul National University Hospital, Korea)

Satellite Symposium 14 (SL14)

Evolving management of mUC in Korea: Case-based insights and treatment strategies

Date & Time	Sep. 5 (Fri), 15:40-16:20	Venue	Room E (Grand Hall 4)
Chair(s)	Jae-Lyun Lee (Asan Medical Center, Korea)
Session Details	1. The evolution of mUC treatment in Korea: The significance of 1L maintenance In Ho Kim (The Catholic University of Korea Seoul St. Mary’s Hospital, Korea) 2. Treatment journey in mUC; Case-based learning Hongsik Kim (Chungbuk National University Hospital, Korea)